FRAMINGHAM, MA — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments and diagnostics, recently announced the publication of a new study, entitled “Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia [BPH]” in Scientific Reports.
As part of the study, BERG evaluated over 750 patients at geographically diverse medical centers in the U.S. and Canada, where they applied the biomarker panel, comprised of filamin-A (FLNA), age and prostate volume, to predict and stratify men with BPH from those with PCa.
(more…)